Ultragenyx Positive Top-Line Phase 3 Study of DTX401 Gene Therapy for Glycogen Storage Disease

 Treatment with DTX401 resulted in a statistically significant reduction in daily cornstarch intake at Week 48 (p<0.0001) with maintenance of glucose control

Company will host investor call today at 5:00 p.m. ET

Conference Call and Webcast Information
Ultragenyx will host a conference call at 5:00 p.m. ET today to discuss the topline data from the DTX401 Phase 3 GlucoGene study. The live and replayed webcast of the call will be available through the company’s website at https://ir.ultragenyx.com/events-presentations.

https://www.globenewswire.com/news-release/2024/05/30/2891103/20739/en/Ultragenyx-Announces-Positive-Top-Line-Results-from-Phase-3-Study-of-DTX401-Gene-Therapy-for-Glycogen-Storage-Disease-Type-Ia-GSDIa.html